Yesterday (Thursday April 17, 2025), Lilly announced significant topline results from its Phase 3 ACHIEVE-1 study, evaluating the safety and efficacy of orforglipron, an oral GLP-1 receptor agonist, in adults with type 2 diabetes. The study found that orforglipron successfully met its primary endpoint by significantly reducing A1C levels compared to a placebo, marking a major milestone in the treatment of type 2 diabetes. Importantly, orforglipron is the first oral GLP-1 medication that has completed a Phase 3 trial, setting it apart from other GLP-1 drugs in the market.
